Document is current
Any future updates will be listed below
-
Authors
Davar, Diwakar https://orcid.org/0000-0002-7846-8055
Cavalcante, Ludimila https://orcid.org/0000-0002-9676-0789
Lakhani, Nehal https://orcid.org/0009-0005-6327-0176
Moser, Justin https://orcid.org/0000-0002-0643-6759
Millward, Michael
McKean, Meredith
Voskoboynik, Mark
Sanborn, Rachel E https://orcid.org/0000-0003-0542-6054
Grewal, Jaspreet S
Narayan, Ajita
Patnaik, Amita
Gainor, Justin F
Sznol, Mario https://orcid.org/0000-0003-4137-9662
Enstrom, Amanda
Blanchfield, Lori
LeBlanc, Heidi
Thomas, Heather
Chisamore, Michael J
Peng, Stanford L
Naumovski, Allison https://orcid.org/0009-0007-3021-6135
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04186637 at ClinicalTrials.govnct04920383 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
https://doi.org/10.1136/jitc-2024-009474
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
https://doi.org/10.1136/jitc-2024-009475
738 Interim dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in advanced malignancies (NEON-2)
https://doi.org/10.1136/jitc-2022-sitc2022.0738
33 Development of a clinical <i>ex vivo</i> assay for the assessment of therapeutic CD28 costimulatory pathway engagement
https://doi.org/10.1136/jitc-2021-sitc2021.033
Documents that mention this clinical trial
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2) (Results)
https://doi.org/10.1136/jitc-2024-009474
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
https://doi.org/10.1136/jitc-2024-009475
738 Interim dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in advanced malignancies (NEON-2)
https://doi.org/10.1136/jitc-2022-sitc2022.0738
497 A Study of ALPN-202, a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies
https://doi.org/10.1136/jitc-2021-sitc2021.497
-
Funding
Funding for this research was provided by:
Alpine Immune Sciences, Inc. (N/A)
- License Information
